LAUSR

istry (IHC), flow cytometry, transcriptome sequencing and targeted DNA sequencing. These studies have demonstrated retention of key architectural, cellular, and molecular features of the primary tumors. Flow cytometric analysis of patient tumors and their respective xenografts revealed highly concordant patterns of surface marker expression. IHC of murine tissues confirmed retention of tumor immunophenotypes, architecture, and even tissue tropism in the PDXs. The genetic characterization of the PDX models using a targeted DNA sequencing approach showed a mutational profile that clearly matched primary lymphoma samples and significantly expands the current repertoire of available pre-clinical models. These models represent a unique opportunity to interrogate biology and perform preclinical studies with in vivo models. We have utilized models extensively to interrogate chemical, antibody and other therapeutic manipulations. The lymphomas, along with a spectrum of PDXs from other hematologic malignancies, are available through the online portal PRoXe (Public Repository of Xenografts) at http://www. proxe.org.